



Metformin Clinical Trial

We need your help!

Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X Syndrome (FXS)

Why do this Study?

We are attempting to further assess Metformin's safety, as well as the potential benefits of Metformin, on delayed language /cognition, excessive eating, obesity, hypogonadism and delayed puberty.

What the participants will do:

The study lasts 4 months and includes 3 clinic visits and 5 phone calls while taking the Metformin. Participants will complete various tasks, questionnaires, and examinations by a physician/research team. Participants will also have blood drawn, as well as urine and stool samples taken.

Who Can Participate?

Individuals aged 6-35 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria)

If you would like to learn more, or would like to participate, contact our study coordinator at **University of Alberta** by phone (**780-492-9461**) or email (metcoord@ualberta.ca), or our study coordinator at **CHU Sainte-Justine** in Montreal by phone (**514-345-4931 ext 2789**) or email (maryse.thibeault@recherche-ste-justine.qc.ca)

You can also visit our website at www.metforminfxs.com

Together we may be able to give those diagnosed with FXS (and their families) a better life experience.



This project is titled: "A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals with Fragile X Syndrome (FXS)". The principal investigators of this study are Dr. Francois Bolduc, MD, PhD, FRCPC (www.bolduclab.com), in the Department of Pediatrics at the University of Alberta and Drs Sebastien Jacquemont, MD and Sarah Lippe, PhD, in the Department of Genetics at CHU Sainte-Justine in Montreal. Pro00081059.

